Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 2
2006 1
2007 5
2008 1
2009 4
2010 12
2011 7
2012 8
2013 5
2014 8
2015 6
2016 11
2017 16
2018 14
2019 8
2020 13
2021 15
Text availability
Article attribute
Article type
Publication date

Search Results

129 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean shridhar ganesan (1 results)?
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, Rathmell WK, Swanstrom R, Parker JS, Serody JS, Selitsky SR, Vincent BG. Smith CC, et al. Among authors: ganesan s. J Clin Invest. 2018 Nov 1;128(11):4804-4820. doi: 10.1172/JCI121476. Epub 2018 Oct 2. J Clin Invest. 2018. PMID: 30137025 Free PMC article.
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S. Jaspers JE, et al. Among authors: ganesan s. Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25. Cancer Discov. 2013. PMID: 23103855 Free PMC article.
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM. Disel U, et al. Among authors: ganesan s. Oncologist. 2020 Jan;25(1):e39-e47. doi: 10.1634/theoncologist.2018-0528. Epub 2019 Oct 11. Oncologist. 2020. PMID: 31604903 Free PMC article.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Silver DP, et al. Among authors: ganesan s. J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100965 Free PMC article.
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH. Sokol ES, et al. Among authors: ganesan s. JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30. JCO Precis Oncol. 2020. PMID: 32903788 Free PMC article.
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.
Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. Bouwman P, et al. Among authors: ganesan s. Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9. Nat Struct Mol Biol. 2010. PMID: 20453858 Free PMC article.
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S. Mehnert JM, et al. Among authors: ganesan s. J Clin Invest. 2016 Jun 1;126(6):2334-40. doi: 10.1172/JCI84940. Epub 2016 May 9. J Clin Invest. 2016. PMID: 27159395 Free PMC article.
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S. Panda A, et al. Among authors: ganesan s. J Natl Cancer Inst. 2018 Mar 1;110(3):316-320. doi: 10.1093/jnci/djx213. J Natl Cancer Inst. 2018. PMID: 29155997 Free PMC article.
Genomic and immunologic correlates of LAG-3 expression in cancer.
Panda A, Rosenfeld JA, Singer EA, Bhanot G, Ganesan S. Panda A, et al. Among authors: ganesan s. Oncoimmunology. 2020 May 22;9(1):1756116. doi: 10.1080/2162402X.2020.1756116. Oncoimmunology. 2020. PMID: 32923111 Free PMC article.
129 results